MX2020010130A - Formulacion y metodo de preparacion. - Google Patents
Formulacion y metodo de preparacion.Info
- Publication number
- MX2020010130A MX2020010130A MX2020010130A MX2020010130A MX2020010130A MX 2020010130 A MX2020010130 A MX 2020010130A MX 2020010130 A MX2020010130 A MX 2020010130A MX 2020010130 A MX2020010130 A MX 2020010130A MX 2020010130 A MX2020010130 A MX 2020010130A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- formulations
- pharmaceutical composition
- formulation
- monitoring
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 3
- 238000012544 monitoring process Methods 0.000 abstract 3
- 238000003384 imaging method Methods 0.000 abstract 2
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 239000013022 formulation composition Substances 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se describen formulaciones para administración humana o animal y a un método de preparación de las mismas. En particular, se describen formulaciones farmacéuticas más estables, tal como aquellas para la administración intravenosa, y a un método de preparación de las mismas. También se describen formulaciones liofilizadas que tiene un ingrediente farmacéutico activo (API), un agente amortiguador y un lioprotector, en donde el API es un agente formador de imágenes que comprende al menos un péptido de unión a cMet, adecuado para formar en imágenes ópticamente el cuerpo de mamífero in vivo. También se describen un método para preparar una formulación liofilizada, una composición farmacéutica, y un kit para la preparación de la composición farmacéutica. Se describen además métodos de formación de imágenes usando la formulación o composición farmacéutica, tal como en la detección, diagnóstico, cirugía, estadificación, tratamiento, vigilancia del tratamiento, vigilancia de la progresión de la enfermedad o vigilancia de la terapia de las afecciones tal como cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1804835.5A GB201804835D0 (en) | 2018-03-26 | 2018-03-26 | Formulation and method of preparation |
| PCT/EP2019/057538 WO2019185607A1 (en) | 2018-03-26 | 2019-03-26 | Formulation and method of preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010130A true MX2020010130A (es) | 2021-01-08 |
Family
ID=62068063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010130A MX2020010130A (es) | 2018-03-26 | 2019-03-26 | Formulacion y metodo de preparacion. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20210046195A1 (es) |
| EP (1) | EP3773750B1 (es) |
| JP (2) | JP2021519300A (es) |
| KR (1) | KR20200136007A (es) |
| CN (1) | CN112203698A (es) |
| AU (1) | AU2019246196A1 (es) |
| BR (1) | BR112020019367A2 (es) |
| CA (1) | CA3094571A1 (es) |
| DK (1) | DK3773750T3 (es) |
| ES (1) | ES2923148T3 (es) |
| GB (1) | GB201804835D0 (es) |
| HR (1) | HRP20220850T1 (es) |
| HU (1) | HUE059216T2 (es) |
| LT (1) | LT3773750T (es) |
| MX (1) | MX2020010130A (es) |
| PL (1) | PL3773750T3 (es) |
| PT (1) | PT3773750T (es) |
| RS (1) | RS63388B1 (es) |
| SG (1) | SG11202009315WA (es) |
| SI (1) | SI3773750T1 (es) |
| WO (1) | WO2019185607A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11709155B2 (en) | 2017-09-18 | 2023-07-25 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes |
| US11709156B2 (en) | 2017-09-18 | 2023-07-25 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved analytical analysis |
| US11918936B2 (en) | 2020-01-17 | 2024-03-05 | Waters Technologies Corporation | Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding |
| AU2022396967A1 (en) * | 2021-11-26 | 2024-06-13 | Astellas Pharma Inc. | Indocyanine compound-containing solid pharmaceutical composition |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10502616A (ja) * | 1994-04-25 | 1998-03-10 | 協和醗酵工業株式会社 | Ｄｘ−５２−１化合物の安定化法及びその凍結乾燥組成物 |
| ES2557286T3 (es) * | 2003-03-03 | 2016-01-25 | Dyax Corp. | Usos de péptidos que se unen específicamente al receptor del HGF (cMet) |
| US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| KR101578225B1 (ko) * | 2007-05-16 | 2015-12-17 | 지이 헬스케어 에이에스 | 영상화를 위한 표지된 ｈｇｆ 결합성 펩티드 |
| EP2030644A1 (en) * | 2007-08-31 | 2009-03-04 | PARI Pharma GmbH | Aerosols for sinunasal drug delivery |
| GB201013808D0 (en) * | 2010-08-18 | 2010-09-29 | Ge Healthcare Ltd | Peptide radiotracer compositions |
| GB201016206D0 (en) * | 2010-09-27 | 2010-11-10 | Ge Healthcare Ltd | Apoptosis imaging agents |
| GB201020314D0 (en) * | 2010-12-01 | 2011-01-12 | Ge Healthcare Ltd | Apoptosis pet imaging agents |
| GB201103696D0 (en) * | 2011-03-04 | 2011-04-20 | Ge Healthcare Ltd | Technetium labelled peptides |
| GB201314936D0 (en) * | 2013-08-21 | 2013-10-02 | Ge Healthcare Ltd | Radiolabelling method |
| US20160143925A1 (en) * | 2013-11-12 | 2016-05-26 | Galenicum Health S.L. | Stable pharmaceutical compositions |
| GB201322456D0 (en) * | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
-
2018
- 2018-03-26 GB GBGB1804835.5A patent/GB201804835D0/en not_active Ceased
-
2019
- 2019-03-26 PT PT197134679T patent/PT3773750T/pt unknown
- 2019-03-26 CA CA3094571A patent/CA3094571A1/en active Pending
- 2019-03-26 JP JP2020551822A patent/JP2021519300A/ja active Pending
- 2019-03-26 DK DK19713467.9T patent/DK3773750T3/da active
- 2019-03-26 AU AU2019246196A patent/AU2019246196A1/en active Pending
- 2019-03-26 WO PCT/EP2019/057538 patent/WO2019185607A1/en active Search and Examination
- 2019-03-26 KR KR1020207030557A patent/KR20200136007A/ko unknown
- 2019-03-26 PL PL19713467.9T patent/PL3773750T3/pl unknown
- 2019-03-26 CN CN201980035582.8A patent/CN112203698A/zh active Pending
- 2019-03-26 SI SI201930276T patent/SI3773750T1/sl unknown
- 2019-03-26 RS RS20220663A patent/RS63388B1/sr unknown
- 2019-03-26 BR BR112020019367-4A patent/BR112020019367A2/pt unknown
- 2019-03-26 EP EP19713467.9A patent/EP3773750B1/en active Active
- 2019-03-26 SG SG11202009315WA patent/SG11202009315WA/en unknown
- 2019-03-26 LT LTEPPCT/EP2019/057538T patent/LT3773750T/lt unknown
- 2019-03-26 MX MX2020010130A patent/MX2020010130A/es unknown
- 2019-03-26 US US17/041,759 patent/US20210046195A1/en active Pending
- 2019-03-26 HR HRP20220850TT patent/HRP20220850T1/hr unknown
- 2019-03-26 ES ES19713467T patent/ES2923148T3/es active Active
- 2019-03-26 HU HUE19713467A patent/HUE059216T2/hu unknown
-
2023
- 2023-12-21 JP JP2023215576A patent/JP2024045106A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK3773750T3 (da) | 2022-07-11 |
| EP3773750A1 (en) | 2021-02-17 |
| RS63388B1 (sr) | 2022-08-31 |
| HUE059216T2 (hu) | 2022-10-28 |
| WO2019185607A1 (en) | 2019-10-03 |
| HRP20220850T1 (hr) | 2022-10-14 |
| CA3094571A1 (en) | 2019-10-03 |
| PT3773750T (pt) | 2022-07-12 |
| ES2923148T3 (es) | 2022-09-23 |
| RU2020134801A (ru) | 2022-04-27 |
| KR20200136007A (ko) | 2020-12-04 |
| AU2019246196A1 (en) | 2020-10-29 |
| GB201804835D0 (en) | 2018-05-09 |
| US20210046195A1 (en) | 2021-02-18 |
| BR112020019367A2 (pt) | 2021-02-17 |
| JP2024045106A (ja) | 2024-04-02 |
| JP2021519300A (ja) | 2021-08-10 |
| PL3773750T3 (pl) | 2022-08-08 |
| LT3773750T (lt) | 2022-07-25 |
| CN112203698A (zh) | 2021-01-08 |
| SG11202009315WA (en) | 2020-10-29 |
| SI3773750T1 (sl) | 2022-09-30 |
| EP3773750B1 (en) | 2022-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010130A (es) | Formulacion y metodo de preparacion. | |
| EA201101518A1 (ru) | Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии | |
| JP6663351B2 (ja) | 温度感受性ヒドロゲル−コラゲナーゼ製剤 | |
| WO2009043527A3 (en) | Therapeutic use of human growth hormone 1-43 | |
| WO2009043476A3 (en) | Neuromedin s as a therapeutic agent | |
| MY171356A (en) | Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections | |
| WO2009046863A3 (en) | Use of thymosin alpha 1 peptide or the combination with the human pancreatic polypeptide as a therapeutic agent | |
| CN104826094A (zh) | 包含增效比例的干扰素γ和α的稳定的制剂 | |
| GB0814302D0 (en) | Compounds and methods | |
| JP2021505667A (ja) | ざ瘡およびバイオフィルムに対するバクテリオファージ処置 | |
| WO2009033755A3 (en) | Use of l-carnosine as a therapeutic agent | |
| KR20200042440A (ko) | 고형종양, 과다색소침착 및 통풍의 전이를 억제하기 위한 완충제의 비경구 비전신적 투여 | |
| JP2017507995A5 (es) | ||
| BR112013005673A2 (pt) | uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes | |
| MX2015000541A (es) | Formulaciones de diclofenaco. | |
| US9682099B2 (en) | Compositions and methods for treating joints | |
| CN111542335A (zh) | 炎症性肠病的治疗药 | |
| WO2009043480A3 (en) | Use of leptin (22-56 ) as a therapeutic agent | |
| RU2012140379A (ru) | Способы и композиции для повышения срока выживаемости жирового трансплантата | |
| WO2012044783A3 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| JP6595717B2 (ja) | 骨関節炎治療のための親水化されたスルファサラジンおよびヒアルロン酸を含む組成物およびその製造方法 | |
| MX2023000004A (es) | Formulaciones para promover la hidratacion y metodos de uso de las mismas. | |
| US20230405063A1 (en) | Use of probiotic component and pharmaceutical composition containing probiotic component | |
| RU2491964C1 (ru) | Способ консервативного лечения эпикондилита плеча | |
| RU2676263C1 (ru) | Способ коррекции поражений печени у больных бруцеллезом |